US bill to restrict WuXi AppTec, Chinese biotechs revised to give more time to cut ties
Add BT as a preferred source
DeeperDive is a beta AI feature. Refer to full articles for the facts.
A NEW version of a bill that would restrict US business with certain Chinese biotechnology companies including WuXi AppTec and BGI would give US companies until 2032 to end work with the firms, extending the amount of time to find new partners.
The latest Biosecure Act also adds WuXi Biologics to a list of biotech companies of concern, according to a copy seen by Reuters. The other companies on the list are BGI, MGI, Complete Genomics and WuXi AppTec.
The revised bill will be introduced on Friday (May 10) and a US House of Representatives committee is expected to decide next week whether to move the bill forward, according to a House Committee on Oversight and Accountability spokesperson.
The committee markup, expected Wednesday, is a procedural step in the process to the bill’s possibly becoming law. A similar Senate bill was approved by a committee there in March.
The bills are designed to keep Americans’ personal health and genetic information from foreign adversaries.
A spokesperson for WuXi Biologics said they had not yet seen the revised bill and could not comment. The other companies listed did not immediately respond to requests for comment.
SEE ALSO
Navigate Asia in
a new global order
Get the insights delivered to your inbox.
The latest bill “highlights a key vulnerability in our global supply chain and importantly provides a reasonable timeframe for companies to decouple their reliance on China-based biomanufacturing,” John Crowley, president of BIO, an industry association, said in a statement. REUTERS
Decoding Asia newsletter: your guide to navigating Asia in a new global order. Sign up here to get Decoding Asia newsletter. Delivered to your inbox. Free.
Share with us your feedback on BT's products and services
TRENDING NOW
S-E Asia tourism takes hit from Middle East crisis, but intra-regional travel could spell hope
Higher costs, lower returns: Why are Singaporeans still betting on real estate?
From 1MDB to ‘corporate mafia’: Is Malaysia facing a new governance test?
China pips the US if Asean is forced to choose, but analysts warn against reading it like a sports result
